A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
Completed · Phase 2 · NCT03222609
Conditions: Myelofibrosis (MF)
At a glance
- Research payments reported, 2025
- $253,022
- U.S. investigators named
- 19
- Sites paid
- 19
- Planned or actual enrollment
- 191
About the trial
- Sponsor
- AbbVie
- Tested
- Ruxolitinib (drug), Navitoclax (drug)
- Dates
- Started 2017-10-31; completion 2025-01-29
- Results posted
- Yes
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
From ClinicalTrials.gov, last updated 2026-01-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $253,022 in research payments for this study in 2025 (42 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Pankit J. Vachhani, MD Hematology & Oncology · Birmingham, AL
- Casey L. O'connell, M.D. Hematology & Oncology · Los Angeles, CA
- Vinod Pullarkat, M.D. Hematology · Duarte, CA
- James Foran, MD Hematology & Oncology · Jacksonville, FL
- Rami S. Komrokji, M.D. Hematology · Tampa, FL
- Maxim Norkin, MD, PHD Hematology · Jacksonville, FL
- Sami M. Ali, M.D. Hematology & Oncology · Snellville, GA
- Olatoyosi Odenike Hematology & Oncology · Chicago, IL
- Felix A. Mensah, MD Hematology · Indianapolis, IN
- Raquel O. Alencar, M.D., PH.D. Radiology · Boston, MA
- Jacqueline Garcia, M.D. Hematology & Oncology · Boston, MA
- Ahmad H. Mattour, M.D. Hematology · Detroit, MI
- Jonathan M. Gerber Hematology · New York, NY
- Ellen K. Ritchie, MD Medical Oncology · New York, NY
- Sarah A. Wall, MD Hematology · Columbus, OH
- Salman Fazal, M.D. Hematology & Oncology · Harrisburg, PA
- Anton M. Melnyk JR., MD,FACP Hematology & Oncology · Abilene, TX
- Naveen Pemmaraju, M.D. Hematology & Oncology · Houston, TX
- Srinivas K. Tantravahi, MD Hematology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $97,399
- Weill Medical College of Cornell University $38,036
- Henry Ford Health Hospital, MI $26,951
- The Ohio State University $19,502
- Mayo Clinic $13,494
- The University of Chicago $12,175
- Texas Oncology PA $7,639
- Baptist Health Medical Center - Jacksonville, FL $7,200
- Allegheny Singer Research Institute $6,390
- University of Alabama Hospital, AL $5,519
- University of Southern California $4,421
- Ut MD Anderson Cancer Center $3,139
- University of Utah Hospital and Clinics, UT $2,939
- University of Massachusetts $2,604
- Toi Clinical Research LLC $2,500
- Dana-Farbermass General Brigham Cancer Care Inc $1,814
- Moffitt Cancer Center $765
- Indiana Blood and Marrow Transplant $347
- Scientia Imaging LLC $190
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.